Trial Profile

Phase IIa Study of Addition of Itacitinib With Tacrolimus/Sirolimus Regimen for GVHD Prophylaxis in Fludarabine and Melphalan Non-Myeloablative Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, MDS or MF

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fludarabine (Primary) ; Itacitinib (Primary) ; Melphalan (Primary) ; Sirolimus (Primary) ; Tacrolimus (Primary) ; Tacrolimus (Primary)
Indications Graft-versus-host disease; Leukaemia; Myelodysplastic syndromes; Myelofibrosis
Focus Therapeutic Use

24 Mar 2025 Planned End Date changed from 22 Dec 2024 to 20 Jan 2026.
21 Nov 2024 According to a City of Hope media release, data from this will be presented in oral poster presentations at ASH annual meeting from Dec. 7 to 10 in San Diego.
27 Jun 2024 Planned End Date changed from 22 May 2024 to 22 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com